Combination therapy does not show superior efficacy in newly diagnosed myeloma

Combination therapy does not show superior efficacy in newly diagnosed myeloma

Combination therapy does not show superior efficacy in newly diagnosed myeloma

The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care--bortezomib, lenalidomide, and dexamethasone (VRd).